XTLB (XTL Biopharmaceuticals) DeferredTaxAndRevenue: $0.00 Mil (As of Dec. 2025)


XTLB XTL Biopharmaceuticals Ltd XTLB
26 GF Score
Price $2.85
! 4 Warning Signs
View Full Analysis

What is XTL Biopharmaceuticals DeferredTaxAndRevenue?

XTL Biopharmaceuticals XTLB -3.56% 26 DeferredTaxAndRevenue is $0.00 Mil as of Dec. 2025. GuruFocus rates XTLB with a GF Score™ of 26/100. The stock has 4 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

XTL Biopharmaceuticals's current deferred tax and revenue for the quarter that ended in Dec. 2025 was $0.00 Mil.

XTL Biopharmaceuticals DeferredTaxAndRevenue Related Terms

XTL Biopharmaceuticals DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for XTL Biopharmaceuticals's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XTL Biopharmaceuticals DeferredTaxAndRevenue Chart

XTL Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.02 0.00

XTL Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.02 0.00 0.00
XTLB
26GF Score
XTL Biopharmaceuticals Ltd XTLB
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.00 Mil mean?
XTL Biopharmaceuticals (XTLB) has a DeferredTaxAndRevenue of $0.00 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on XTL Biopharmaceuticals.
Is XTL Biopharmaceuticals' DeferredTaxAndRevenue too high?
XTL Biopharmaceuticals' current DeferredTaxAndRevenue is $0.00 Mil. Overall, XTL Biopharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' DeferredTaxAndRevenue compare to VRTX and REGN?
XTL Biopharmaceuticals' DeferredTaxAndRevenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on XTL Biopharmaceuticals. XTL Biopharmaceuticals's current DeferredTaxAndRevenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current DeferredTaxAndRevenue of $0.00 Mil. The current DeferredTaxAndRevenue is $0.00 Mil. XTL Biopharmaceuticals' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current DeferredTaxAndRevenue is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XTL Biopharmaceuticals Business Description

Other Exchanges XTLB:IsraelHHB0:Germany
Address 26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
26GF Score

Get the complete analysis for XTLB

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.85
Price